HKMSS 11th Annual Scientific Meeting
Dr. Eppie Yiu
University of Melbourne
Dr. Daniel O'Neill
Prof. Noriko Isobe
Dr. Stephen Cheng
Ms Sharon Chiu
Pamela Youde Nethersole Eastern Hospital
Prof. Wei Qiu
Sun Yat-sen University
On 15 October 2022, the HKMSS held its 11th Annual Scientific Meeting as a virtual webinar. Despite being a half day event, we had to honour to learn from international, regional and local experts.
Paediatric multiple sclerosis and related disorders
Dr. Eppie Yiu from the University of Melbourne, Australia, began with her talk ‘Paediatric multiple sclerosis and related disorders’, where she highlighted the differences between childhood and adult MS.
MS pathology: new insights and potential implications for treatment. The role of cladribine in disease treatment and control
Dr. Daniel O’Neill from Liver Hospital, Australia, then enlightened us on ‘MS pathology: new insights and potential implications for treatment’, where he discussed the role of cladribine in disease treatment and control.
Optimising the use of DMTs for long-term benefit of MS treatment
Prof. Noriko Isobe from Kyushu University, Japan, next shared her expertise on ‘Optimising the use of DMTs for long-term benefit of MS treatment’, during which she gave a special focus on extended interval use of Natalizumab.
Multiple sclerosis functional assessment
Our Vice President, Dr. Stephen Cheng, was then joined by Ms Sharon Chiu, an Occupational Therapist working at PYNEH, and talked about ‘Multiple sclerosis functional assessment’, exploring tools other than the EDSS.
Clinical experience on B-cell therapy in Multiple Sclerosis: Role of Ofatumumab and differentiating it from Rituximab
In the last talk of the symposium, Prof. Wei Qiu from Sun Yat-sen University, China, shared on his ‘Clinical experience on B-cell therapy in Multiple Sclerosis’, where he focused on the role of Ofatumumab and how it differentiates from Rituximab.
We would like to thank all our speakers and chairpersons for making this a successful event!